In W1 ovarian cancer cells, 33 evoked enhanced effects on cell viability compared to singleor combination treatment with the unconjugated Sirt2 and HDAC6 inhibitors.Thus, our dual Sirt2/HDAC6 inhibitors are highly interesting new toolsto investigate the consequences and the therapeutic potential of dualinhibition of the two tubulin deacetylases Sirt2 and HDAC6. Here, HDAC6 is linked to ovarian cancer.